Prosecution Insights
Last updated: November 04, 2026

Byo Holdings LLC

Technology area: Biotechnology & Pharmaceuticals

2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready

Analysis

Byo Holdings LLC has 2 pending office actions currently active in the Biotechnology & Pharmaceuticals technology area. These actions are being handled by 2 distinct examiners, though they are both located within 1 distinct art unit. This concentration in 1 distinct art unit suggests a consistent technical focus, even as the work is divided among different individuals.

The busiest examiner identified in the data is MISHRA, DEEPA, who accounts for 1 pending office action. With 2 distinct examiners managing the 2 pending office actions, the portfolio experiences a high degree of examiner variety relative to its size. This distribution requires the applicant to adapt to the specific preferences of different examiners within the same art unit.

The strategy for the Biotechnology & Pharmaceuticals portfolio must account for the 2 distinct examiners involved. While the 1 distinct art unit provides a stable procedural baseline, the individual interpretations of the examiners may vary. Success in these 2 pending office actions will depend on the ability to maintain a cohesive narrative while addressing the unique concerns raised by MISHRA, DEEPA and the other assigned examiner.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

2
Total Pending OAs
2
Non-Final OAs
0
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

1
Overdue
0
Due this week
0
Due this month
0
Due in next 60 days
0
Due later

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

2
Hard (100%)
0
Medium (0%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§101 + other2 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

2
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

20 h
Manual time on pending OAs
4 h
Time saved (low, 20%)
7 h
Time saved (mid, 35%)
0.2 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
MISHRA, DEEPA 1 28.2% +36.1%
BREEN, KIMBERLY CATHERINE 1 23.8% +56.3%

Hard Cases (2)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.

App #TitleExaminerDue in
17064826 INDIGENOUS AND IMPROVED FUNGALLY FERMENTED CBD, CBG AND RELATED CANNABINOID ORAL DOSAGE FORMS MISHRA, DEEPA 119d overdue
16839343 Indigenous and Improved Bacterially Fermented CBD, CBG and Related Cannabinoid Oral Dosage Forms BREEN, KIMBERLY CATHERINE —

Interview Candidates (2)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.

App #TitleExaminerDue in
17064826 INDIGENOUS AND IMPROVED FUNGALLY FERMENTED CBD, CBG AND RELATED CANNABINOID ORAL DOSAGE FORMS MISHRA, DEEPA 119d overdue
16839343 Indigenous and Improved Bacterially Fermented CBD, CBG and Related Cannabinoid Oral Dosage Forms BREEN, KIMBERLY CATHERINE —

Top Art Units

Art UnitApps
1657 2

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
17064826 INDIGENOUS AND IMPROVED FUNGALLY FERMENTED CBD, CBG AND RELATED CANNABINOID ORAL DOSAGE FORMS MISHRA, DEEPA 1657 §101§103DP Non-Final OA 119d overdue Pending Oct 07, 2020
16839343 Indigenous and Improved Bacterially Fermented CBD, CBG and Related Cannabinoid Oral Dosage Forms BREEN, KIMBERLY CATHERINE 1657 §101§103§112DP Non-Final OA — Pending Apr 03, 2020

Managing Byo Holdings LLC's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Byo Holdings LLC have?

Byo Holdings LLC has 2 pending office actions as of November 2026, spread across 1 art units and 2 examiners.

Which USPTO examiner handles the most Byo Holdings LLC applications?

Deepa Mishra has the most, with 1 of Byo Holdings LLC's pending office actions.

What technology area are Byo Holdings LLC's patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month